



TO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

|                        |                                   |
|------------------------|-----------------------------------|
| Application Number     | 10/684,796                        |
| Filing Date            | October 14, 2003                  |
| First Named Inventor   | GARMAN, JONATHAN<br>DAVID         |
| Art Unit               | <del>1644</del> 1646              |
| Examiner Name          | <del>4233</del> Zachary C. Howard |
| Attorney Docket Number | VITA-019                          |

1

of

2

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
|                       |                          | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
| /ZH/                  |                          | US-5,994,506                             | 11-30-1999                     | Soppet, et al.                                     |   |
| /ZH/                  |                          | US-6,406,871                             | 06-18-2002                     | Pausch, et al.                                     |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear | T <sup>4</sup> |
|-----------------------|--------------------------|---|--------------------------------|--|---|----------------|
|                       |                          | Country Code <sup>3</sup> - Number <sup>2</sup> - Kind Code <sup>2</sup> (if known) |                                |  |   |                |
| /ZH/                  |                          | WO 00/13161   | 03-09-2000                     | Mellander  |   |                |
| /ZH/                  |                          | WO 00/69897   | 11-23-2000                     | Lu   |   |                |
| /ZH/                  |                          | WO 00/69898   | 11-23-2000                     | Lu   |   |                |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the<br>item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),<br>publisher, city and/or country where published. | T <sup>4</sup> |
|-----------------------|--------------------------|---|----------------|
| /ZH/                  |                          | AARTS, et al., "Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95<br>protein interactions," (2002) <i>Science</i> , 298:846-850   |                |
|                       |                          | ANGLIN, et al., "Review Induction of prostate apoptosis by $\alpha_1$ -adrenoceptor antagonists:<br>mechanistic significance of the quinazoline component," (2002) <i>Prostate Cancer and<br/>Prostatic Diseases</i> , 5(2):88-95                                     |                |
|                       |                          | DEBEIR, et al., "Protective effects of the $\alpha_1$ -adrenoceptor antagonist, dexeproxan, against<br>degeneration of the basolateral cholinergic system induced by cortical devascularization<br>in the adult rat," (2002) <i>Neuroscience</i> , 115(1):41-53       |                |
|                       |                          | DJAVAN, "Lower urinary tract systems/benign prostatic hyperplasia: fast control of the<br>patient's quality of life," (2003) <i>Urology</i> , 62:6-14   |                |
|                       |                          | GOWING, et al., "Alpha2 adrenergic agonists for the management of opioid withdrawal<br>(Review)," (2003) <i>Cochrane Database Syst Rev</i> , (2):CD002024   |                |
|                       |                          | GREGORINI, et al., "Effects of selective $\alpha_1$ - and $\alpha_2$ -adrenergic blockade on coronary flow<br>reserve after coronary stenting," (2002) <i>Circulation</i> , 106:2901-2907   |                |
|                       |                          | POOL, et al., "Clinical significance of $\alpha_1$ -adrenoceptor selectivity in the management of<br>benign prostatic hyperplasia," (2001) <i>International Urology and Nephrology</i> , 33:407-412   |                |
|                       |                          | PUPO, et al., "Interaction of neuronal nitric oxide synthase with alpha <sub>1</sub> -adrenergic receptor<br>subtypes in transfected HEK-293 cells," (2002) <i>BMC Pharmacology</i> , 2:17  |                |

|                       |                  |                    |            |
|-----------------------|------------------|--------------------|------------|
| Examiner<br>Signature | /Zachary Howard/ | Date<br>Considered | 06/20/2007 |
|-----------------------|------------------|--------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |  |   |
|---|---|----|---|--------------------------|--|---|
| Substitute for form 1449/PTO<br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |  |   |
|   |   |    |   | Application Number       |  | 10/684,796                              |
|   |   |    |   | Filing Date              |  | October 14, 2003                        |
|   |   |    |   | First Named Inventor     |  | GARMAN, JONATHAN DAVID                  |
|   |   |    |   | Art Unit                 |  | <del>1644</del> 1646                    |
|   |   |    |   | Examiner Name            |  | <del>Unassigned</del> Zachary C. Howard |
| Sheet   | 2 | of | 2 | Attorney Docket Number   |  | VITA-019                                |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                   | T <sup>2</sup>  |            |
|--------------------|-----------------------|---|-----------------|------------|
| ZH/                |                       | ROEHRBORN, "Are all $\alpha$ -blockers created equal? An update," (2002) <i>Urology</i> 59:3-6  |                 |            |
|                    |                       | SAVOLA, et al., "Flipamezole (JP-1730) is a potent $\alpha_2$ adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's Disease," (2003) <i>Movement Disorders</i> , 18(8):872-883  |                 |            |
|                    |                       | STEWART, et al., "Clinical and physiological effects of an acute $\alpha$ -1 adrenergic agonist and a $\beta$ -1 adrenergic antagonist in chronic orthostatic intolerance," (2002) <i>Circulation</i> , 106:2948-2954   |                 |            |
|                    |                       | STONE, et al., "Emerging evidence for a central epinephrine-innervated $\alpha_1$ -adrenergic system that regulates behavioral activation and is impaired in depression," (2003) <i>Neuropsychopharmacology</i> , 28:1387-1399  |                 |            |
|                    |                       | TATTON, et al., "Hypothesis for a common basis for neuroprotection in glaucoma and alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation," (2003) <i>Survey of Ophthalmology</i> , 48sup1:S25-S37   |                 |            |
|                    |                       | TEETERS, et al., "Systemic $\alpha_{1A}$ -adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery," (2003) <i>American Journal of Physiology (Heart and Circulation Physiology)</i> , 284:H385-H392   |                 |            |
|                    |                       | VELLIQUETTE, et al., "The role of 1-imidazoline and $\alpha_2$ -adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X," (2003) <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 306(2):646-657 |                 |            |
|                    |                       | WHEELER, et al., "Role of alpha-2 agonists in neuroprotection," (2003) <i>Survey of Ophthalmology</i> 48sup1:S47-S51  |                 |            |
| ▼                  |                       | WILLEMS, et al., "Possible role of $\alpha$ -adrenoceptor subtypes in acute migraine therapy," (2003) <i>Cephalalgia</i> , 23:245-257   |                 |            |
| Examiner signature |                       | /Zachary Howard/  | Date Considered | 06/20/2007 |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.